Ceryvyn Therapeutics (CYV) Investor presentation summary

Strategic focus and company rebuilding

• Transitioning to a rare disease company centered on VEGFR-3 biology and OPT-302, targeting rare pulmonary and lymphatic diseases with high unmet need.

• OPT-302 leverages extensive prior human experience and a capital-efficient, disciplined execution model.

• Reinstatement on ASX and operational rebuilding are underway, with a streamlined structure and outsourced development.

• Company is leveraging $120m prior investment in OPT-302 manufacturing and clinical development.

Scientific and clinical rationale

• OPT-302 is a VEGF-C/D "trap" protein designed to block VEGFR-3 signaling, directly addressing lymphatic dysfunction in LAM.

• LAM is a rare, progressive lung disease affecting women, with no existing cure and significant unmet need.

• VEGF-C/D biology is strongly implicated in LAM pathology, and OPT-302's mechanism is well-characterized and de-risked.

• The approach aims to stabilize lung function and slow disease progression by dampening abnormal lymphatic signaling.

Operational and clinical progress

• Reinstated on ASX as of June 2026, with $31.2 million in cash and no debt.

• Engaged with specialist rare disease partners and established a Scientific Advisory Board with global LAM experts.

• Preclinical development of nebulized OPT-302 is on track, with strong safety and biological data in large animals.

• Stage-gated development plan includes rigorous milestones and stop criteria, with early human studies planned.